- Home
- CCCC vs ZBIO Comparison
CCCC vs ZBIO Comparison
Compare CCCC & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- ZBIO
- Stock Information
- Founded
- CCCC 2015
- ZBIO 2019
- Country
- CCCC United States
- ZBIO United States
- Employees
- CCCC N/A
- ZBIO N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- CCCC Health Care
- ZBIO
- Exchange
- CCCC Nasdaq
- ZBIO NYSE
- Market Cap
- CCCC 244.9M
- ZBIO 268.7M
- IPO Year
- CCCC 2020
- ZBIO 2024
- Fundamental
- Price
- CCCC $3.01
- ZBIO $7.83
- Analyst Decision
- CCCC Buy
- ZBIO Strong Buy
- Analyst Count
- CCCC 5
- ZBIO 6
- Target Price
- CCCC $11.60
- ZBIO $29.20
- AVG Volume (30 Days)
- CCCC 1.8M
- ZBIO 207.0K
- Earning Date
- CCCC 03-04-2025
- ZBIO 03-04-2025
- Dividend Yield
- CCCC N/A
- ZBIO N/A
- EPS Growth
- CCCC N/A
- ZBIO N/A
- EPS
- CCCC N/A
- ZBIO N/A
- Revenue
- CCCC $33,668,000.00
- ZBIO N/A
- Revenue This Year
- CCCC $75.59
- ZBIO N/A
- Revenue Next Year
- CCCC N/A
- ZBIO N/A
- P/E Ratio
- CCCC N/A
- ZBIO N/A
- Revenue Growth
- CCCC 65.45
- ZBIO N/A
- 52 Week Low
- CCCC $2.79
- ZBIO $5.83
- 52 Week High
- CCCC $11.88
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- CCCC 33.55
- ZBIO N/A
- Support Level
- CCCC $2.79
- ZBIO N/A
- Resistance Level
- CCCC $3.38
- ZBIO N/A
- Average True Range (ATR)
- CCCC 0.20
- ZBIO 0.00
- MACD
- CCCC -0.03
- ZBIO 0.00
- Stochastic Oscillator
- CCCC 23.66
- ZBIO 0.00
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.